The effectiveness of popular, non-prescription weight loss supplements

Egger, Garry; Cameron-Smith, David; Stanton, Rosemary

Topics

Complementary therapies

The effectiveness of popular, non-prescription weight loss supplements

Correspondence:

1.
Popkin BM, Doak CM. The obesity epidemic is a worldwide phenomenon. Nutr Rev 1998; 56: 106-114.
2.
Australian Bureau of Statistics. National Nutrition Survey. Canberra: ABS, 1998. (Catalogue No 4805.0.)
3.
Egger G, Swinburn B. An ecological approach to the obesity pandemic. BMJ 1997; 315: 477-480.
4.
National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinical practice guidelines. Canberra: NHMRC, 1999.
5.
Flatt J-P. Body fat content and balance between fat and alcohol oxidation and consumption. In: Dalton S, editor. Overweight and weight management. Gaithersburg, Md: Aspen Publications, 1997: 224-253.
6.
Vasselli JR, Maggio CA. Mechanisms of appetite control and body weight regulation. In: Dalton S, editor. Overweight and weight management. Gaithersburg, Md: Aspen Publications, 1997: 187-208.
7.
Badmaev V, Majeed M. Open field, physician controlled, clinical evaluation of botanical weight loss formula citrin. Paper presented to Nutracon 1995, Nutriceutical, Dietary Supplements and Functional Foods, and reported in Heymsfield SB, Allison DB, Vasselli JR, et al. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomised controlled trial. JAMA 1998; 11: 280: 1596-1600.
8.
Conte AA. A non-prescription alternative on weight reduction therapy. Am J Bariat Med, Summer 1993: 17-19.
9.
Thom E. Hydroxycitrate (HCA) in the treatment of obesity [abstract]. Paper presented to the European Conference on Obesity, Barcelona, 1996. Int J Obes 1996; 20: 111.
10.
Rothacker DQ, Waitman BE. Effectiveness of a Garcinia cambogia and natural caffeine combination in weight loss: a double-blind placebo-controlled pilot study [abstract]. Int J Obes 1997; 21 Suppl 2: 53.
11.
Girola M, De Bernardi M, Conti S, et al. Dose effect in lipid lowering activity of a new dietary integrator (chitosan, Garcinia cambogia extract, and chrome). Acta Toxicol Ther 1996; 17: 25-40.
12.
Heymsfield SB, Allison DB, Vasselli JR, et al. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomised controlled trial. JAMA 1998; 280: 1596-1600.
13.
Buck SH, Burks TF. The neuropharmacology of capsaicin: review of some recent observations. Pharmacol Rev 1986; 38: 179-226.
14.
MacLean DB. Abrogation of peripheral cholecystokinin-satiety in the capsaicin treated rat. Regul Pept 1985; 11: 321-333.
15.
Tremblay A. Obesity and health: what can we learn from intervention studies? [abstract]. Paper presented to the Australasian Society for the Study of Obesity, 8th Annual Meeting, Sydney 1999. ASSO Proceedings. Melbourne: ASSO, 1999: 38.
16.
Henry CJ, Emery B. Effect of spiced food on metabolic rate. Hum Nutr Clin Nutr 1986; 40: 165-168.
17.
Edwards SJ, Montgomery IM, Colquhoun EQ, et al. Spicy meal disturbs sleep: an effect of thermoregulation? Int J Psychophysiol 1992; 13: 97-100.
18.
Colquhoun E. Possible new pharmacological approaches to the management of obesity [abstract]. Paper presented to the Australian Society for the Study of Obesity, 2nd Annual Meeting, Melbourne, 1993. ASSO Proceedings. Melbourne: ASSO, 1983: 35.
19.
Williams SR, Clark RF, Dunford JV. Contact dermatitis associated with capsaicin: human hand syndrome. Ann Emerg Med 1995; 25: 713-715.
20.
Dodd SL, Herb RA, Powers SK. Caffeine and exercise performance. Sports Med 1993; 15: 14-23.
21.
Arciero PJ, Gardner AW, Calles-Escandon J, et al. Effects of caffeine ingestion on NE kinetics, fat oxidation, and energy expenditure in younger and older men. Am J Physiol 1995; 268(6 Pt 1): E1192-E1198.
22.
Bracco D, Ferrarra J-M, Arnaud MJ, et al. Effects of caffeine on energy metabolism in lean and obese women. Am J Physiol 1995; 269: E671-E678.
23.
Astrup A, Toubro S, Cannon S, et al. Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers. Am J Clin Nutr 1990; 51: 759-767.
24.
Horton TJ, Geissler CA. Post-prandial thermogenesis with ephedrine, caffeine and aspirin in lean, pre-disposed obese and obese women. Int J Obes 1996; 20: 91-97.
25.
Graham TE, Rush JWE, van Soeren MH. Caffeine and exercise: metabolism and performance. Can J Appl Physiol 1994: 19; 111-138.
26.
Cole KJ, Costill DL, Starling RD, et al. Effect of caffeine ingestion on perception of effort and subsequent work production. Int J Sports Nutr 1996; 6: 14-23.
27.
Astrup A, Breum L, Toubro S, et al. The effect and safety of an ephedrine/caffeine compound compared with ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes 1992; 16: 269-277.
28.
Astrup A, Buemann B, Christensen NJ, et al. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. Metabolism 1992; 41: 686-688.
29.
Breum L, Pedersen JK, Ahlstrom F, Frimodt-Moller J. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice. Int J Obes 1994; 18: 99-103.
30.
Buemann B, Marckmann P, Christensen NJ, Astrup A. The effect of ephedrine plus caffeine on plasma lipids and lipoproteins during a 4.2 MJ/day diet. Int J Obes 1994; 18: 329-332.
31.
Daly PA, Krieger DR, Dulloo AG, et al. Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. Int J Obes 1993; 17 Suppl 1: S73-S78.
32.
Pasman WJ, Westerterp-Plantenga MS, Saris WH. The effectiveness of long-term supplementation of carbohydrate, chromium, fibre and caffeine on weight maintenance. Int J Obes 1997; 21: 1143-1151.
33.
Toubro S, Astrup AV, Breum L, Quaade F. Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture Int J Obes 1993; 17 Suppl 1: S69-S72.
34.
International Life Sciences Institute. Caffeine: a scientific review. Food Technol Aust 1988, January Suppl.
35.
Vukovich MD, Costill DL, Fink WJ. Carnitine supplementation: effect on muscle carnitine and glycogen content during exercise. Med Sci Sports Exerc 1994; 26: 1122-1129.
36.
Sulkers EJ, Lafeber HN, Degenhart HJ, et al. Effects of high carnitine supplementation on substrate utilization in low-birth-weight infants receiving total parenteral nutrition. Am J Clin Nutr 1990; 52: 889-894.
37.
Heinonen OJ. Carnitine and physical activity. Sports Med 1996; 22: 109-114.
38.
Ventura P. Lipid lowering activity of chitosan, a new dietary integrator. In: Muzzarelli RAA, editor. Chitin enzymology, Vol. 2. Ancona, Italy: Atec Edizioni, 1996: 55-62.
39.
Maezaki Y, Tsuji K, Nakawa, et al. Hypocholesterolaemic effect of chitosan in adult males. Biosc Biochem Biotech 1993; 57: 1439-1444.
40.
Veneroni G, Veneroni F, Contos S, et al. Effect of a new chitosan on hyperlipidaemia and overweight in obese patients. In: Muzzarelli RAA, editor. Chitin enzymology, Vol. 2. Ancona, Italy: Atec Edizioni, 1996: 63-67.
41.
Abelin J, Lassus AL. 112 Bipolymer - Fat [binder] as a weight reducer in patients with moderate obesity. Medical research report. A study performed at Ars Medicina, Helsinki, August-October, 1994.
42.
Columbo P, Sciutto AM. Nutritional aspects of chitosan employment in hypocaloric diet. Acta Toxicol Ther 1996; 17: 278-302.
43.
Veneroni G, Veneroni F, Contos S, et al. Effect of a new chitosan dietary integrator and hypocaloric diet on hyperlipidemia and overweight in obese patients. Acta Toxicol Therap 1996; 17: 53-70.
44.
Macchi G. A new approach to the treatment of obesity: chitosan's effects on body weight reduction and plasma cholesterol levels. Acta Toxicol Ther 1996; 17: 303-320.
45.
Giustina A, Ventura P. Weight-reducing regimens in obese subjects: effects of a new dietary fibre integrator. Acta Toxicol Ther 1995; 16: 199-214.
46.
Sciutto AM, Columbo P. Lipid-lowering effect of chitosan dietary integrator and hypocaloric diet in obese patients. Acta Toxicol Ther 1995; 16: 215-230.
47.
Ernst E, Pittler MH. A meta-analysis of chitosan for body weight reduction. Perfusion 1998; 11: 461-465.
48.
Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomized, double-blind trial of chitosan for body weight reduction. Eur J Clin Nutr 1999; 53: 379-381.
49.
Evans GW. The effect of chromium picolinate on insulin controlled parameters in humans. Int J Biosoc Med Res 1989; 11: 163-180.
50.
Kaats GR, Fischer JA, Blum K. The effects of chromium picolinate supplementation on body composition in different age groups [abstract]. Am Aging Assoc Abstr 1991; 21: 138.
51.
Anderson RA, Polansky MM, Bryden NA, et al. Chromium supplementation of human subjects: effects on glucose, insulin, and lipid variables. Metabolism 1983; 32: 894-899.
52.
Anderson RA. Effects of chromium on body composition and body weight. Nutr Rev 1998; 56: 266-270.
53.
Grant KE, Chandler RM, Castle AL, Ivy JL. Chromium and exercise training: effect on obese women. Med Sci Sports Exerc 1997; 29: 992-998.
54.
Stearns DM, Belbruno JJ, Wetterhahn KE. A prediction of chromium (III) accumulation in humans from chromium dietary supplements. FASEB J 1995; 9: 1650-1657.
55.
Cerulli J, Grabe DW, Gauthier I, et al. Chromium picolinate toxicity. Ann Pharmacother 1998; 32: 428-431.
56.
Gaigi S, Elati J, Ben Osman A, Beji C (Experimental study of the effects of seaweed in the treament of obesity) (Article in French). Tunis Med 1996; 74: 241-243.
57.
Marceilhac A, Drakine N, Bourhim N, et al. Effect of chronic administration of Ginkgo biloba extract or ginkgolide on the hypothalamic-pituitary-adrenal axis in the rat. Life Sci 1998; 62: 2329-2340.
58.
White HL, Scates PW, Cooper BR. Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. Life Sci 1996; 58: 1315-1321.
59.
Striegel-Moore R, Rodin J. The influence of psychological variables in obesity. In: Brownell KD, Foreyt JP, editors. Handbook of eating disorders. NewYork: Basic Books, 1986: 99-121.
60.
Rapin JR, Lamproglou I, Drieu K, DeFeudis FV. Demonstration of the "anti-stress" activity of an extract of Ginkgo biloba (EGb761) using a discrimination learning task. Gen Pharmacol 1994; 25: 1009-1016.
61.
Chan BSH, Graudins A, Whyte IM, et al. Serotonin syndrome resulting from drug interactions. Med J Aust 1998; 169: 523-525.
62.
Nuttall FQ. Dietary fiber in the management of diabetes. Diabetes 1993; 42: 503-508.
63.
Tiwary CM, Ward JA, Jackson BA. Effect of pectin on satiety in healthy US Army adults. J Am Coll Nutr 1997; 16: 423-428.
64.
Matzkies F, Budelski I, Webs B. Effect of a fiber-containing dietary formula on metabolism. Fortschr Med 1982; 100: 917-920.
65.
Pasman WJ, Westerterp-Plantenga MS, Muls E, et al. The effectiveness of long-term fibre supplementation on weight maintenance in weight-reduced women. Int J Obes 1997; 21: 548-555.
66.
Livesey G. Fibre as energy in man. In: Kretchevsky D, Bonfield C, editors. Dietary fibre in health and disease. Eagan, Minnesota: Eagan Press, 1995: 46-57.
67.
Bjorvell H, Rossner, S. Long-term effects of commonly available weight reducing programmes in Sweden. Int J Obes 1987; 11: 67-71.
68.
Baird DD, Umbach DM, Lansdell L, et al. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women. J Clin Endocrinol Metab 1995; 80:1685-1690.
69.
Linde K, Ramirez G, Mulrow CD, et al. St John's wort for depression -- an overview and meta-analysis of randomised clinical trials. BMJ 1996; 313: 253-258.

Online responses are no longer available. Please refer to our instructions for authors page for more information.